Status and phase
Conditions
Treatments
About
The goal of this study is to evaluate short course radiation in the post-operative female pelvis after hysterectomy in stage III-IVA endometrial adenocarcinoma patients, or any stage patients with uterine serous or carcinosarcoma histology. The investigators hypothesize that short course pelvic radiation will have an acute and late grade 3-4 toxicity rate < 10%, and patients will benefit from both convenient and effective loco-regional control comparable to the traditional 5-6 weeks of radiation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologically or cytologically confirmed stage IIIA-IVA endometrial cancer, or any stage I-IVA where any proportion of the tumor is uterine serous, clear cell, de-differentiated, or carcinosarcoma histology.
Must have already undergone radical hysterectomy. Hysterectomy may have occurred no more than one year prior to enrollment.
At least 18 years of age.
ECOG performance status ≤ 2
Minimal bone marrow and organ function as defined below:
Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
25 participants in 1 patient group
Loading...
Central trial contact
Jessika Contreras, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal